We are live on ! Find out more
AAA

Affinity Asset Advisors Portfolio holdings

AUM $1.94B
1-Year Est. Return 374.45%
This Fund
S&P 500
This Quarter Est. Return
-7.11%
1 Year Est. Return
+374.45%
3 Year Est. Return
+1,279.72%
5 Year Est. Return
+2,528.28%
10 Year Est. Return
–
AUM
$237M
AUM Growth
-$388M
Cap. Flow
-$385M
Cap. Flow %
-162.18%
Top 10 Hldgs %
53.02%
Holding
76
New
17
Increased
16
Reduced
11
Closed
22

Top Buys

Rank Stock Value
1
ESTA icon
Establishment Labs
ESTA
+$11.8M
2
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$4.31M
3
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$4.26M
4
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$1.84M
5
LNTH icon
Lantheus
LNTH
+$1.58M

Top Sells

Rank Stock Value
1
SWTX
SpringWorks Therapeutics
SWTX
+$13.9M
2
PTGX icon
Protagonist Therapeutics
PTGX
+$7.1M
3
MORF
Morphic Holding, Inc. Common Stock
MORF
+$6.98M
4
NSTG
NanoString Technologies, Inc.
NSTG
+$5.96M
5
AZN icon
AstraZeneca
AZN
+$4.92M

Sector Composition

Rank Sector Weight
1 Healthcare 63.86%
2 Financials 1.44%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRNA icon
26
CALL
Moderna
MRNA
$23.6B
$2.14M 0.9%
+15,000
New +$2.14M
ZNTL icon
27
Zentalis Pharmaceuticals
ZNTL
$357M
$1.97M 0.83%
70,000
-137,500
-66% -$3.64M
CNTX icon
28
Context Therapeutics
CNTX
$56.6M
$1.87M 0.79%
883,654
+106,044
+14% +$199K
VINC
29
DELISTED
Vincerx Pharma, Inc. Common Stock
VINC
$1.81M 0.76%
68,705
– –
FATE icon
30
CALL
Fate Therapeutics
FATE
$325M
$1.67M 0.71%
+67,500
New +$1.86M
IOVA icon
31
CALL
Iovance Biotherapeutics
IOVA
$2.24B
$1.66M 0.7%
+150,000
New +$1.97M
ACRS icon
32
Aclaris Therapeutics
ACRS
$778M
$1.4M 0.59%
100,000
– –
ACLX
33
DELISTED
Arcellx
ACLX
$1.36M 0.57%
+75,000
New +$968K
NAUT icon
34
Nautilus Biotechnolgy
NAUT
$215M
$1.25M 0.53%
466,607
-92,412
-17% -$344K
COGT icon
35
Cogent Biosciences
COGT
$6.54B
$1.13M 0.48%
+125,000
New +$853K
CLDX icon
36
Celldex Therapeutics
CLDX
$2.78B
$1.08M 0.45%
40,000
-85,000
-68% -$2.47M
TERN
37
DELISTED
Terns Pharmaceuticals
TERN
$995K 0.42%
+401,268
New +$801K
LIAN
38
DELISTED
LianBio American Depositary Shares
LIAN
$972K 0.41%
450,000
+125,000
+38% +$424K
SPRY icon
39
ARS Pharmaceuticals
SPRY
$640M
$721K 0.3%
+170,000
New +$593K
CELU icon
40
PUT
Celularity
CELU
$22.6M
$624K 0.26%
18,360
+10,360
+130% +$841K
CYTK icon
41
Cytokinetics
CYTK
$10.7B
$589K 0.25%
+15,000
New +$604K
SNCE
42
DELISTED
Science 37 Holdings, Inc. Common Stock
SNCE
$562K 0.24%
13,989
+2,920
+26% +$213K
RCOR
43
DELISTED
Renovacor, Inc.
RCOR
$405K 0.17%
199,490
– –
LNAI
44
PUT
Lunai Bioworks
LNAI
$12M
$386K 0.16%
+2,500
New +$1.14M
IMTXW
45
DELISTED
Immatics N.V. Warrants
IMTXW
$382K 0.16%
187,204
– –
CRIS icon
46
Curis
CRIS
$8.81M
$335K 0.14%
851
-24
-3% -$10K
VRDN icon
47
Viridian Therapeutics
VRDN
$2.05B
$239K 0.1%
20,660
-29,340
-59% -$394K
PNT
48
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
$174K 0.07%
+25,578
New +$196K
MSACW
49
DELISTED
Medicus Sciences Acquisition Corp. Warrant
MSACW
$8K ﹤0.01%
33,333
– –
RCOR.WS
50
DELISTED
Renovacor, Inc. Warrants, entitling the holder thereof to purchase one-half (1/2) of a share of common stock at a price of $11. 50 per whole share
RCOR.WS
$5K ﹤0.01%
75,000
– –
1
2
3

Similar funds

FM
Foster & Motley Cincinnati, Ohio $1.94B AUM 21.65% 1-Year Est. Return
1SB
1ST Source Bank South Bend, Indiana $1.94B AUM 20.3% 1-Year Est. Return
HCL
Heard Capital LLC Chicago, Illinois $1.93B AUM 21.66% 1-Year Est. Return
OCM
Osterweis Capital Management San Francisco, California $1.94B AUM 20.77% 1-Year Est. Return
MWA
Midland Wealth Advisors Effingham, Illinois $1.94B AUM 14.31% 1-Year Est. Return
AF
Advisornet Financial Minnetonka, Minnesota $1.93B AUM 18.43% 1-Year Est. Return
NFG
Nations Financial Group Cedar Rapids, Iowa $1.94B AUM 25.76% 1-Year Est. Return
HC
Hamilton Capital Columbus, Ohio $1.93B AUM

Affinity Asset Advisors's Q2 2022 Portfolio in Review

As of Q2 2022, Affinity Asset Advisors held 76 positions worth $237M, down 62% from $625M the previous quarter. Its ten largest holdings account for 53% of the portfolio.

Affinity Asset Advisors withdrew a net $385M in Q2 2022, closing 22 positions and reducing 11 holdings. Its most notable exit was SpringWorks Therapeutics, an estimated $13.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 64% of assets, up from 34% a quarter earlier, followed by Financials.

Against the trend, Affinity Asset Advisors opened a new position in Arcellx worth $1.36M.

  • Affinity Asset Advisors's largest Q2 2022 buy was Arcellx: 75,000 shares worth $1.36M.
  • Affinity Asset Advisors added most to Establishment Labs in Q2 2022, an estimated $11.8M increase.
  • Affinity Asset Advisors's biggest Q2 2022 reduction was Morphic Holding, Inc. Common Stock, cutting an estimated $6.98M.
  • Affinity Asset Advisors fully exited SpringWorks Therapeutics in Q2 2022, selling an estimated $13.9M.
  • Affinity Asset Advisors's ten largest holdings make up 53% of its $237M portfolio in Q2 2022.
  • Affinity Asset Advisors opened 17 new positions and closed 22 in Q2 2022.
  • Affinity Asset Advisors's portfolio value fell 62% quarter-over-quarter to $237M.

Based on Affinity Asset Advisors's 13F filing for Q2 2022, filed 12 Aug 2022.